VOLTAIRE-X: Pharmacokinetics, Safety, Immunogenicity and Efficacy of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: a Randomized, Double-blind, Parallel-arm, Multiple-dose, Active Comparator Trial
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics; Registrational
- Acronyms VOLTAIRE-X
- Sponsors Boehringer Ingelheim
- 18 Sep 2018 Planned number of patients changed from 240 to 350.
- 24 Jul 2018 Planned End Date changed from 19 Jul 2019 to 15 Jul 2020.
- 24 Jul 2018 Planned primary completion date changed from 28 Feb 2019 to 12 Mar 2020.